Table 1

Patient characteristics
Characteristic No. of patients %
No. of enrolled 15 100.0%
Age, y
Median 56
Range 44-66
Chemotherapy
neoadjuvant 3 20.0%
adjuvant 10 66.7%
palliative 2 13.3%
tumor hormone receptor
ER(+), PR(+) 5 33.3%
ER(+), PR(-) 3 20.0%
ER(-), PR(+) 1 6.7%
ER(-), PR(-) 5 33.3%
not applicable 1 6.7%
Her2/neu
Absent 5 33.3%
1+ 3 20.0%
2+ 4 26.7%
3+ 2 13.3%
not applicable 1 6.7%
GCSF administration
Yes 7 46.7%
No 8 53.3%
pT stage*
pT1 3 20.0%
pT2 9 60.0%
pT3 0 0.0%
pT4 3 20.0%
pN stage*
pN0 6 40.0%
pN1 4 26.7%
pN2 3 20.0%
pN3 1 6.7%
not applicable 1 6.7%
Tumor grade
grade 1 2 13.3%
grade 2 6 40.0%
grade 3 6 40.0%
not applicable 1 6.7%
Distant metastases
Yes 2 13.3%
No 13 86.7%
Chemotherapy regimen
Anthracycline-based 7 46.7%
Taxane-based 7 46.7%
Others** 2 13.3%

*pT, pN stage: according to definition of AJCC 7th edition staging system.

**Others include: liposomal doxorubicin, vinorelbine. ER: estrogen receptor; PR: progesterone receptor; GCSF: Granulocyte colony-stimulating factor.

Kuo et al.

Kuo et al. BMC Cancer 2012 12:620   doi:10.1186/1471-2407-12-620

Open Data